Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

The present invention improves an existing contrast agent, especially, a T1 contrast agent, and adopts a strategy in which the T1 contrast material is partially coated on a support surface to which a hydrophilic functional group is exposed. The partial coating strategy adopted in the present invention improves both the stability and contrast performance of T1 contrast agent nanoparticles, and such a strategy leads to very interesting technical development.

The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

Nanoparticulate material suitable for administration to a subject, the nanoparticulate material having bound to its surface: (a) copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid, wherein the copolymeric steric stabiliser comprises (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric steric stabiliser to the nanoparticulate material, and (ii) a steric stabilising polymer segment that is different from the anchoring polymer segment, and (b) copolymeric mapping moiety comprising (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric mapping moiety to the nanoparticulate material, (ii) one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP), and (iii) a coupling polymer segment that is different to the anchoring polymer segment, wherein the coupling polymer segment couples the anchoring polymer segment to the one or more mapping groups.

A method of improving targeted delivery of at least one of a treatment agent, an imaging agent and a diagnostic agent attached to magneto-aerotactic-responsive bacteria; it includes adapting a total bolus escape time of a solution of the magneto-aerotactic responsive bacteria in order to influence the targeting of a target zone with hypoxic zones in the patient.

A conjugate for treating an individual suffering from a disease, wherein the conjugate is comprised of: a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; and at least one therapeutic molecule and methods for making and administering same. Also disclosed is a combination product for use in the treatment of a disease, wherein the combination product comprises: (a) a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; (b) a liposome, wherein the targeting peptide is encapsulated within the liposome; and (c) an effective amount of an anti-inflammatory agent and methods for making and administering same.

A location within a patient may be visualized while reducing potential impact on the patient's anatomy. A contrast media may be injected into a location within the patient's vasculature. The location may be viewed fluoroscopically. At least some of the injected contrast media may be recaptured in order to reduce a quantity of contrast media reaching the patient's anatomy.

The present invention belongs to the technical field of fluorescence detection, and specifically relates to a multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques and the use thereof. The multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques is Fe.sub.3O.sub.4-A12-Cy7. The probe of the present invention is Fe.sub.3O.sub.4-A12-Cy7, wherein protein A12 is a single-domain antibody that can specifically bind to PlexinD1, that is, probe Fe.sub.3O.sub.4-A12-Cy7 can specifically bind to PlexinD1, thus achieving the optimization of the target. According to the present invention, FLI/MPI/CTA is fused to form multi-modal imaging. The multi-modal imaging has the advantages of a high sensitivity and a high spatial resolution, can realize early warning and dynamic monitoring of atherosclerotic plaques, and can also visually reflect 3D stereoscopic imaging, thereby providing theoretical support and technical support for basic research.

A ferrite nano-composites with synergistic enhancement of liver specificity and preparation method and application thereof, wherein the ferrite nano-composites have both manganese ions and ethoxybenzyl group, and the molar percentage of ethoxybenzyl group to manganese ions is 25-60%. The molar percentages of manganese and ferric ions in the ferrite nanoparticles are 40-80%, and the ferrite nano-composites with manganese ions and ethoxybenzyl groups on the surface are in the particle size range of 0.2-5 nm, with preferred particle size range of 2-4 nm. With the preparation method and the application for magnetic resonance T1 imaging, the ferrite nano-composites enhance hepatocyte specificity due to the synergistic effect of manganese ions and ethoxybenzyl groups, thus achieving enhanced T1 imaging of the liver with high specificity in magnetic resonance imaging.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.